The combination of exercise and psychedelics for the treatment of major depressive disorder

Major depressive disorder is common and disabling, and although antidepressants and psychotherapy help many people, a substantial proportion do not respond adequately. The extracted text frames exercise and psychedelics as two alternative approaches that have each shown positive effects on depression in isolation, but notes that their combined or synergistic potential has not been adequately explored. The paper sets out to review the evidence and identify gaps concerning the possible combination of exercise and psychedelics for treating major depressive disorder. It is presented as an opinion piece rather than an original trial, aiming to draw together biological, psychological, behavioural, and pharmacokinetic considerations that could explain why the two interventions might complement one another.

The extracted text does not describe an empirical study design, participant sample, or formal review protocol. Instead, the article appears to be a narrative opinion piece that synthesises existing literature on exercise, psychedelic-assisted therapy, and depression. The authors organise the paper thematically. They first summarise exercise as a treatment for depression, then psychedelic-assisted psychotherapy, and then discuss potential synergy between the two. They also consider overlapping biological pathways, possible psychological and behavioural mechanisms, and how exercise might alter psychedelic pharmacokinetics and pharmacodynamics. The paper does not clearly report database searches, inclusion criteria, risk-of-bias assessment, or statistical methods, which suggests it is not a systematic review or meta-analysis in the conventional sense, despite the metadata label.

Because this is an opinion-style paper, there are no original study results, effect estimates, or pooled analyses reported in the extracted text. The paper instead summarises findings from earlier research to support the idea that exercise and psychedelics might be complementary in depression treatment. For exercise, the authors state that physical activity is protective against depression, can be an effective treatment with efficacy similar to first-line approaches such as medication or therapy, and cite a number needed to treat of 2. They also note reported benefits for neuroplasticity, suicide prevention, and general health. For psychedelics, the paper states that meta-analyses have found medium effect sizes on clinician-rated measures in major depressive disorder, with trials suggesting effects comparable to antidepressant medications and persisting after the drug is no longer present. The authors also mention reported increases in neuroplasticity and potential reductions in suicidal ideation. The rest of the section is largely mechanistic. The authors argue that exercise and psychedelics share several overlapping pathways, including brain-derived neurotrophic factor signalling, glutamatergic transmission, serotonin 5-HT 2A receptor activity, hippocampal neurogenesis, default mode network connectivity, dopaminergic signalling, and the endogenous opioid system. They also note behavioural observations from prior studies in which some psychedelic users reported greater openness, improved exercise habits, healthier lifestyles, and reduced alcohol or other substance use. In addition, they describe exercise-related changes in drug absorption, distribution, metabolism, and excretion that could affect psychedelic exposure, as well as preclinical findings that exercise mitigated MDMA-induced mitochondrial dysfunction and hyperthermia in rodent models.

The authors conclude that exercise and psychedelic-assisted therapies each appear promising for depression, but that their combination has not yet been formally tested. They interpret the overlapping biological, psychological, and behavioural mechanisms as suggesting plausible synergy rather than simple additivity. They place the idea in the context of earlier research showing independent benefits for both exercise and psychedelics, while emphasising that the combined approach remains largely speculative. The paper argues that exercise might amplify or sustain psychedelic-induced neuroplasticity, while psychedelic treatment might reduce barriers such as low energy, anhedonia, and lack of motivation that can interfere with physical activity in depression. The authors also suggest that shared interpersonal and behavioural elements, such as integration groups or group exercise, could be mutually reinforcing. The main limitation is the absence of direct empirical evidence on the combined intervention. The authors explicitly note that no study has directly tested the proposed mechanisms in this context, and that questions remain about efficacy, tolerability, safety, and neurobiology. They also point to possible pharmacokinetic and safety issues, including thermoregulation and cardiovascular load during exercise, which may be relevant when psychedelics are used alongside physical activity. Overall, the paper argues for future research on the combination in major depressive disorder and possibly related chronic conditions with overlapping symptom burdens, such as fibromyalgia.

The authors’ final conclusion is that, although exercise and psychedelic-assisted therapies each have evidence of benefit for depression, their combination has not yet been formally explored. They contend that multiple complementary mechanisms make the approach worthy of further study, and they call for research into efficacy, tolerability, safety, and neurobiology.